Indications › Type 2 diabetes

GLP‑1 drugs in type 2 diabetes

Which incretin agents are being studied in type 2 diabetes, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file

596

Active

94

Results scheduled

51

Molecules studied

17

Sponsors

195

FDA-approved for type 2 diabetes: dulaglutide · exenatide · liraglutide · lixisenatide · semaglutide · tirzepatide. Approval wording is on each drug page, quoted from the label.

6 of the molecules tracked here are FDA-approved for type 2 diabetes, so the trials below are asking further questions rather than establishing whether the class works at all. 491 of the 596 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 105 still in early phases. 195 distinct sponsors are involved, 407 of the trials run commercially and the rest by universities and hospitals.

Molecules studied in this indication

albiglutide in this indication · aleniglipron · cagrilintide · danuglipron · dulaglutide in this indication · ecnoglutide · exenatide in this indication · liraglutide in this indication · lixisenatide in this indication · maridebart cafraglutide · mazdutide · orforglipron · petrelintide · retatrutide · semaglutide in this indication · survodutide · tirzepatide in this indication

Results due in this indication

Trials on file

All 596 incretin trials recorded in this indication, active first.